Biotalys NV (BTLS) Fair Value & Analysis
Basic Materials · BE · Market cap €144M
Fair value as of: Jun 24, 2026
Analysis
Biotalys NV (BTLS) currently trades at €3.16, while our model-based Fair Value estimate is €0.8000 — implying the stock looks roughly 74.6% overvalued today. We read business quality at 95/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Biotalys NV, an agricultural technology company, discovers and develops protein-based biocontrol solutions in Belgium and internationally. The company offers biofungicides and bioinsecticides. It also provides the AGROBODY Foundry technology platform, which generates protein-based crop protection products. In addition, the company develops EVOCA 1st generation, EVOCA Next generation, and BIOFUN-6 targeting botrytis, powdery mildew, and other fungi in fruits and vegetables; BIOFUN-7 targeting leafspot disease in cowpeas and other legumes; BIOFUN-4 targeting oomycetes in fruits and vegetables; BIOFUN-8 targeting altenaria in fruits, vegetables, and specialty crops; and BioIns-2 targeting key insect pests. The company was formerly known as Agrosavfe NV and changed its name to Biotalys NV in December 2019. Biotalys NV was incorporated in 2013 and is headquartered in Ghent, Belgium.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Biotalys NV (BTLS) undervalued?
What is the fair value of BTLS?
What is the quality score of BTLS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.